[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659649":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":24,"armGroups":36,"interventions":50,"overallOfficials":66,"centralContacts":24,"locations":24,"responsibleParty":70,"collaborators":24,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":24,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":24,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":24,"overallStatus":91,"whyStopped":24,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":24},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"Time to First Worsening of Pulmonary Sarcoidosis (PS)","Worsening of PS is based on clinical judgment of worsening PS, along with pulmonary function tests and\u002For impaired or unacceptable loss of quality of life as measured by the King's Sarcoidosis Questionnaire (KSQ)-lung score. The time to first worsening of PS will be reported.","Up to approximately 52 weeks",[14,17,21],{"measure":15,"description":16,"timeFrame":12},"Number of Participants Experiencing Worsening of PS","Worsening of PS is based on clinical judgment of worsening PS, along with pulmonary function tests and\u002For impaired or unacceptable loss of quality of life as measured by the KSQ-lung score. The number of participants with worsening of PS will be reported.",{"measure":18,"description":19,"timeFrame":20},"Number of Participants With One or More Adverse Events (AEs)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more adverse events will be reported.","Up to approximately 66 weeks",{"measure":22,"description":23,"timeFrame":12},"Number of Participants Who Discontinue Study Drug Due to One or More AEs","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study drug due to one or more AEs will be reported.",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":24,"primaryPurpose":28,"observationalModel":24,"timePerspective":24,"maskingInfo":29},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":30,"maskingDescription":24,"whoMasked":31},"QUADRUPLE",[32,33,34,35],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[37,44],{"label":38,"type":39,"description":40,"interventionNames":41},"Tulisokibart","EXPERIMENTAL","Participants receive background therapy of prednisone plus tulisokibart.",[42,43],"Drug: Tulisokibart","Drug: Background prednisone therapy",{"label":45,"type":46,"description":47,"interventionNames":48},"Placebo","PLACEBO_COMPARATOR","Participants receive background therapy of prednisone plus placebo.",[49,43],"Other: Placebo",[51,58,62],{"type":52,"name":38,"description":53,"armGroupLabels":54,"otherNames":55},"DRUG","Subcutaneous (SC) administration",[38],[56,57],"MK-7240","PRA023",{"type":59,"name":45,"description":60,"armGroupLabels":61,"otherNames":24},"OTHER","SC administration",[45],{"type":52,"name":63,"description":64,"armGroupLabels":65,"otherNames":24},"Background prednisone therapy","Oral administration",[45,38],[67],{"name":68,"affiliation":5,"role":69},"Medical Director","STUDY_DIRECTOR",{"type":71,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100659649","phase-2-a-clinical-trial-of-tulisokibart-mk-7240-in-participants-with-pulmonary-sarcoidosis-mk-7240-016-100659649",false,"NCT07867938","A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)","A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue biopsy\n* Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening\n* Has active PS within 3 months before Screening\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of cancer and is disease free for \\\u003C5 years\n* Has cardiac, ocular, neurosarcoidosis, or other manifestations of sarcoidosis that requires systemic treatment that may interfere with protocol specifications, or has a clinically significant electrocardiogram abnormality that requires evaluation or intervention\n* Is receiving treatment for pulmonary hypertension\n* Has a history of fungal respiratory infection within 12 months before screening without documentation of completed treatment\n* Has a diagnosis of or currently has a clinical presentation consistent with Löfgren syndrome\n* Has active tuberculosis (TB) or history of active TB\n* Has any condition that may interfere with the ability to adhere to oral corticosteroid therapy or taper\n* Is a current smoker defined as smoking or vaping of inhaled preparations of nicotine, tobacco, or cannabis preparations within 6 months before Screening","ALL","18 Years","75 Years",{"count":83,"type":84},158,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).\n\nThis trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.",[90],"Pulmonary Sarcoidosis","NOT_YET_RECRUITING","2026-10-05",{"date":94,"type":95},"2026-10-09","ACTUAL",{"date":97,"type":84},"2026-11-06",{"date":99,"type":84},"2030-01-11",{"name":5,"class":6}]